Latest News-Telix Pharmaceuticals Corporate Limited Mediaroom_Page

ZIRCON Phase III Renal Cancer Study to be Presented at ASCO GU along with Theranostic Pipeline Advances

* Complete data from global Phase III ZIRCON study of Telix's investigational imaging agent TLX250...

2022-12-22 06:04 3354

Telix Announces Executive Leadership Appointments

MELBOURNE, Australia, Dec. 5, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, ...

2022-12-05 06:39 3002

Illuccix® Available on High Activity Gallium Generator Technology to Meet High Demand

INDIANAPOLIS, Nov. 22, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Com...

2022-11-22 20:00 3069

First Patient Dosed in Phase II 'IPAX-Linz' Study of TLX101 for Glioblastoma Therapy

MELBOURNE, Australia, Nov. 22, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix,...

2022-11-22 04:59 3918

Telix Acquires Optimal Tracers

MELBOURNE, Australia and INDIANAPOLIS, Ind., Nov. 14, 2022 /PRNewswire/ -- Telix Pharmaceuticals Li...

2022-11-14 06:36 4160

Telix to Present at Jefferies London Healthcare Conference 2022

MELBOURNE, Australia, Nov. 11, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix,...

2022-11-11 20:00 6675

Telix Announces Positive Topline Results of ZIRCON Phase III Kidney Cancer Imaging Study

Summary of Study Outcomes * ZIRCON Phase III study of Telix's investigational imaging agent TLX25...

2022-11-07 06:48 2690

Telix Recognised as Company of the Year at AusBiotech and Johnson & Johnson Innovation Industry Excellence Awards 2022

MELBOURNE, Australia, Oct. 27, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix,...

2022-10-27 10:23 4198

Telix and UniQuest to Collaborate on Radiolabelled Immune Targeting Peptide

MELBOURNE, Australia, Oct. 27, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix,...

2022-10-27 06:44 3777

Telix Reports Third Quarter 2022 Financial Results

MELBOURNE, Australia, Oct. 20, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix,...

2022-10-20 06:09 2614

TLX250-CDx Indication Expansion: Preliminary Data Presented at EANM

* OPALESCENCE Phase II feasibility study of TLX250-CDx in patients with triple-negative breast ca...

2022-10-18 06:43 2337

Telix Partnership Expands GE Healthcare Immuno-Diagnostics Offering to the Global Clinical Research Market

* New agreement adds two Telix investigational PET imaging radiotracers to GE Healthcare's immuno...

2022-10-17 13:00 2987

Telix Partnership Expands GE Healthcare Immuno-Diagnostics Offering to the Global Clinical Research Market

Chinese NMPA Approves Pivotal Phase III Study of TLX591-CDx for Prostate Cancer Imaging

MELBOURNE, Australia, Oct. 17, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix,...

2022-10-17 07:25 2469

Health Canada Approves Illuccix® for Prostate Cancer Imaging

MELBOURNE, Australia, Oct. 14, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix,...

2022-10-14 08:21 2662

First Patient in New Zealand Dosed with Illuccix® - Telix's Prostate Cancer Imaging Agent

MELBOURNE, Australia, Sept. 30, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix...

2022-09-30 02:30 3464

Chinese NMPA Approves Study of Telix Kidney Cancer Imaging Candidate

MELBOURNE, Australia, Sept. 28, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix...

2022-09-28 06:50 2462

First Patient in Australia Dosed with Illuccix® - Telix's Approved Prostate Cancer Imaging Agent

MELBOURNE, Australia, Sept. 28, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix...

2022-09-28 05:00 3085

First Patient Enrolled in ProstACT TARGET Study

MELBOURNE, Australia, Sept. 27, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix...

2022-09-27 05:00 2863

Final IPAX-1 Study Data Confirms Safety and Tolerability Profile for TLX101, Preliminary Efficacy Data

MELBOURNE, Australia, Sept. 21, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix...

2022-09-21 07:51 2187

Targeted Alpha Therapy Candidate: Bladder Cancer Study Completes Enrolment

MELBOURNE, Australia and NANTES, France, Aug. 24, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limite...

2022-08-24 05:56 4582